EHA2024 |The IMROZ study

  Рет қаралды 179

Myeloma Patients Europe

Myeloma Patients Europe

Күн бұрын

Doctor Thierry Facon, professor of Haematology at Lille University Hospital in France explains the results of the Phase 3 IMROZ study, comparing isatuximab, bortezomib, lenalidomide and dexamethasone, known as Isa-VRd, versus VRd for transplant-ineligible patients with newly diagnosed myeloma at the European Hematology Association annual congress in Madrid, Spain.

Пікірлер
EHA 2024 | CAMMA 2 study
4:58
Myeloma Patients Europe
Рет қаралды 151
Oh No! My Doll Fell In The Dirt🤧💩
00:17
ToolTastic
Рет қаралды 13 МЛН
Whoa
01:00
Justin Flom
Рет қаралды 55 МЛН
王子原来是假正经#艾莎
00:39
在逃的公主
Рет қаралды 25 МЛН
WILL IT BURST?
00:31
Natan por Aí
Рет қаралды 42 МЛН
Treatment of myelodysplastic syndromes (MDS)
6:01
VJHemOnc – Video Journal of Hematology & HemOnc
Рет қаралды 4,7 М.
Novel Anti-Cancer Agents for Multiple Myeloma
2:06
Mechanisms in Medicine
Рет қаралды 2 М.
Looking forward to EHA 2024: key clinical trials to look out for in the myeloma space
1:15
VJHemOnc – Video Journal of Hematology & HemOnc
Рет қаралды 284
How Multiple Myeloma is Diagnosed?
1:34
The Binding Site
Рет қаралды 1,2 М.
MPE Webinar | EHA 2024 myeloma highlights
1:01:14
Myeloma Patients Europe
Рет қаралды 496
Bortezomib and lenalidomide as first-line treatment for older patients with myeloma
2:35
VJHemOnc – Video Journal of Hematology & HemOnc
Рет қаралды 1,4 М.
MPE/ALAN Webinar | EU HTA
55:55
Myeloma Patients Europe
Рет қаралды 467
Oh No! My Doll Fell In The Dirt🤧💩
00:17
ToolTastic
Рет қаралды 13 МЛН